4//SEC Filing
Ingalls Kerry D. 4
Accession 0001209191-22-014377
CIK 0001661460other
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 7:29 PM ET
Size
7.3 KB
Accession
0001209191-22-014377
Insider Transaction Report
Form 4
Ingalls Kerry D.
Chief Operating Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2022-03-01+72,568→ 72,568 totalExercise: $3.42Exp: 2032-02-29→ Common Stock (72,568 underlying) - Award
Common Stock
2022-03-01+50,000→ 52,000 total
Footnotes (2)
- [F1]Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
- [F2]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.
Documents
Issuer
Poseida Therapeutics, Inc.
CIK 0001661460
Entity typeother
Related Parties
1- filerCIK 0001816804
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Mar 1, 7:29 PM ET
- Size
- 7.3 KB